Accessing CAR T-cell therapy in Italy is hindered by uneven geographic distribution of centers, complex regional reimbursement processes, and strict eligibility criteria. While AIFA-approved, 70% of qualified clinics are concentrated in four northern and central regions, leaving five southern regions without local access.
- Geographic disparities: Treatment hubs are limited to cities like Milan and Rome, requiring patient relocation.
- Reimbursement delays: Transitioning from national to regional funding creates administrative bottlenecks and lengthy local appeals.
- Regulatory bottlenecks: AIFA often maintains stricter age and fitness limits than standard EMA guidelines.
- Referral fragmentation: Lack of a national referral system causes delays in identifying eligible patients.
Bookimed Expert Insight: While standard CAR T pathways involve long waits, Milan remains the strategic choice for international and local patients. Clinics like San Raffaele combine massive clinical research with high-volume hematology departments. Their role in gene therapy trials often provides earlier access to technology than smaller regional centers.
Patient Consensus: Patients report that while public coverage exists, the 6 to 12-month wait times often necessitate early involvement of advocacy groups. Most recommend securing complete treatment documentation immediately to expedite the complex reimbursement appeals process.
